MorphoSys AG (MOR)
18.14
-0.28
(-1.52%)
USD |
NASDAQ |
Jun 14, 16:00
18.10
-0.04
(-0.22%)
After-Hours: 20:00
MorphoSys Research and Development Expense (Annual): 307.04M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 307.04M |
| December 31, 2022 | 314.07M |
| December 31, 2021 | 266.47M |
| December 31, 2020 | 159.16M |
| December 31, 2019 | 121.39M |
| December 31, 2018 | 125.63M |
| December 31, 2017 | 128.33M |
| December 31, 2016 | 103.99M |
| December 31, 2015 | 87.28M |
| December 31, 2014 | 74.42M |
| December 31, 2013 | 65.28M |
| Date | Value |
|---|---|
| December 31, 2012 | 48.43M |
| December 31, 2011 | 77.91M |
| December 31, 2010 | 62.17M |
| December 31, 2009 | 54.34M |
| December 31, 2008 | 40.51M |
| December 31, 2007 | 30.49M |
| December 31, 2006 | -21.94M |
| December 31, 2005 | -17.46M |
| December 31, 2004 | 15.41M |
| December 31, 2003 | 10.19M |
| December 31, 2002 | 18.53M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
121.39M
Minimum
2019
314.07M
Maximum
2022
233.63M
Average
266.47M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Novartis AG | 11.37B |
| Affimed NV | 102.80M |
| InflaRx NV | 44.41M |
| BioNTech SE | 1.930B |
| Immatics NV | 128.47M |